NCT06714526View on ClinicalTrials.gov

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Intracranial Atherosclerosis
Interventions
GENETIC

Point-of-Care CYP2C19 Testing

Genetic testing with the Genomadix cube to determine P2Y12 inhibitor

DRUG

ticagrelor + aspirin

If patients are poor or intermediate metabolizers of clopidogrel, they will receive ticagrelor (90 mg PO BID) + aspirin (81 mg PO daily)

DRUG

clopidogrel + aspirin

Normal, rapid, and ultra-rapid metabolizers of clopidogrel will receive 75 mg PO daily of clopidogrel and 81 mg PO daily of aspirin.

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

University of Calgary, Calgary

M4N3M5

RECRUITING

Dr. Mark I. Boulos - Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER